{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28single+dose%29&page=2",
    "query": {
      "intervention": "Placebo (single dose)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 4600,
    "total_pages": 460,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28single+dose%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28single+dose%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T07:05:12.007Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03272165",
      "title": "Single Ascending Dose Study of MEDI1341 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "MEDI1341",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-10-17",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272165"
    },
    {
      "nct_id": "NCT03830463",
      "title": "Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CTP-692",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Concert Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2019-01-24",
      "completion_date": "2019-03-28",
      "has_results": false,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03830463"
    },
    {
      "nct_id": "NCT00679263",
      "title": "Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "MN-221",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 17,
      "start_date": "2008-02",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2011-12-19",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "North Dartmouth",
          "state": "Massachusetts"
        },
        {
          "city": "Rolla",
          "state": "Missouri"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679263"
    },
    {
      "nct_id": "NCT05496465",
      "title": "Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urticaria"
      ],
      "interventions": [
        {
          "name": "ARS-1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ARS Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2022-07-28",
      "completion_date": "2024-02-29",
      "has_results": true,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496465"
    },
    {
      "nct_id": "NCT06592833",
      "title": "Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-02-25",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06592833"
    },
    {
      "nct_id": "NCT03158038",
      "title": "Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Monovalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 300,
      "start_date": "2017-05-30",
      "completion_date": "2017-12-14",
      "has_results": true,
      "last_update_posted_date": "2019-01-04",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 2,
      "location_summary": "Stockbridge, Georgia • Portland, Oregon",
      "locations": [
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03158038"
    },
    {
      "nct_id": "NCT02376036",
      "title": "Phase 1 Study of MGD010 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "MGD010",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 73,
      "start_date": "2015-02",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02376036"
    },
    {
      "nct_id": "NCT07839871",
      "title": "Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "RSVpreF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 920,
      "start_date": "2026-09-28",
      "completion_date": "2031-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 1,
      "location_summary": "South Euclid, Ohio",
      "locations": [
        {
          "city": "South Euclid",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07839871"
    },
    {
      "nct_id": "NCT03446599",
      "title": "Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vasoplegia",
        "Hypotension",
        "Coronary Artery Disease",
        "Cardiac Valve Disease"
      ],
      "interventions": [
        {
          "name": "Hydroxocobalamin",
          "type": "DRUG"
        },
        {
          "name": "Methylene Blue",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-11",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03446599"
    },
    {
      "nct_id": "NCT05045144",
      "title": "A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSVPreF3(120 μg)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Flu Quadrivalent influenza vaccine (15 μg HA)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1586,
      "start_date": "2021-10-26",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-10-02T07:05:12.007Z",
      "location_count": 5,
      "location_summary": "West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05045144"
    }
  ]
}